Malignant Breast Neoplasm

A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy. ABCB1 C3435T carriers had a longer progression-free survival (p = 0.039) along… (full text at CIViC)

PMID 22906996 · Kim et al., 2012 · Open in CIViC

A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy. ABCB1 G2677T carriers had a longer progression-free survival (p = 0.037) along… (full text at CIViC)

PMID 22906996 · Kim et al., 2012 · Open in CIViC

44 cell lines and 145 patient samples were utilized in various aspects of this study. 31 breast cancer cell lines for in vitro sensitivity to paclitaxel and Monomethyl Auristatin E (MMAE). Genome wide… (full text at CIViC)

PMID 18593940 · O'Brien et al., 2008 · Open in CIViC

mRNA expression of AGR2 in 61 patients with tamoxifen treated postmenopausal breast cancer was determined by qRT-PCR and was inversely associated with treatment response and progression free survival … (full text at CIViC)

PMID 24167368 · Hrstka et al., 2013 · Open in CIViC

Phase 2 trial of capivasertib in AKT1/2/3 activated solid cancer patients. One pre-treated AKT1 D323G-mutant breast cancer patient with ER-positive HER2-negative mixed ductal and lobular carcinoma had… (full text at CIViC)

PMID 35440569 · Shrestha Bhattarai et al., 2022 · Open in CIViC

Breast cancer cell lines with the AKT1 E17K mutation did not show sensitivity to AKT inhibitor MK-2206, unlike cell lines with PIK3CA mutations.

PMID 23888070 · Beaver et al., 2013 · Open in CIViC

In a phase-I study of AZD5363, partial response was observed in 2 patients with breast and ovarian carcinoma, respectively, and AKT1 E17K mutations. While full study results have not yet been publishe… (full text at CIViC)

PMID 26351323 · Davies et al., 2015 · Open in CIViC

In HER2+ metastatic breast cancer treated with trastuzumab (n = 74 patients), the expression of AKT2 and pAkt-Thr308 and/or pAkt-Ser473 localized in nucleus+cytoplasm was associated with an improved t… (full text at CIViC)

PMID 22842582 · Grell et al., 2012 · Open in CIViC

Upregulation of AKT3 due to epigenetic reprogramming may confer acquired resistance to AKT inhibitor (MK2206) in breast cancer preclinical model.

PMID 27297869 · Stottrup et al., 2016 · Open in CIViC

Overexpression of AKT3 in lumenal breast cancer cell line SKBR3, which does not express the AKT3 isoform, induced a statistically significant 2.7 fold increase in IC50 for pan-AKT inhibitor GSK690693.… (full text at CIViC)

PMID 24335962 · Chin et al., 2014 · Open in CIViC

In-vitro and xenograft studies of response of breast cancer cell lines to PI3K/mTOR inhibitor NVP-BEZ235 showed that sensitivity correlated with expression of the androgen receptor (AR). Reintroductio… (full text at CIViC)

PMID 24356815 · Wang et al., 2014 · Open in CIViC

13 HER2 breast cancer patients were treated with trastuzumab and then trastuzumab + docetaxel prior to surgery. Pretreatment biopsies and post-treatment surgical samples were obtained, and microarray … (full text at CIViC)

PMID 23204226 · Chakrabarty et al., 2013 · Open in CIViC

In an attempt to block both MAPK and PI3K/Akt pathways, two signaling inhibitors (sorafenib, a BRAF kinase inhibitor, and ceramide, an agent that dephosphorylates Akt) were used in cell culture and mo… (full text at CIViC)

PMID 18519791 · Tran et al., 2008 · Open in CIViC

Subprotocol R of the NCI-MATCH study tested the MEK inhibitor trametinib in non-V600 BRAF mutant tumors. 32 patients were eligible and received therapy with trametinib. Of these 1 patient had a confir… (full text at CIViC)

PMID 31924734 · Johnson et al., 2020 · Open in CIViC

In a clinical study of 49 patients, 10 patients with Breast Cancer (BC) and wild-type BRAF gene were treated with Cetuximab. After 16 weeks, no clinical activity was observed. PFS of 6.7 weeks (95% CI… (full text at CIViC)

PMID 33090333 · Fisher et al., 2020 · Open in CIViC

In a Portuguese family with 6 cases of breast cancer and 1 of ovarian cancer, a 46 year old woman was diagnosed with breast cancer. She was negative for BRCA1/2 mutations using standard methods but a … (full text at CIViC)

PMID 16088935 · Teugels et al., 2005 · Open in CIViC

In an in vivo study, tumor xenografts expressing delta11q show decreased tumor volume compared to xenografts expressing FL when treated with cisplatin. No difference is seen when treated with rucapari… (full text at CIViC)

PMID 27197267 · Wang et al., 2016 · Open in CIViC

Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1… (full text at CIViC)

PMID 34081848 · Tutt et al., 2021 · Open in CIViC

The authors show that in the CX-5461 and CX-3543, G-quadruplex stabilizing agents, demonstrate specific toxicity against BRCA deficient breast cancer derived cells and polyclonal patient-derived xenog… (full text at CIViC)

PMID 28211448 · Xu et al., 2017 · Open in CIViC

In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.0… (full text at CIViC)

PMID 25847936 · Isakoff et al., 2015 · Open in CIViC

In a study of 26 patients with breast cancer, 10 patients were BRCA-positive and 16 patients were BRCA-negative. Regardless of BRCA status, none showed objective response when treated with olaparib.

PMID 21862407 · Gelmon et al., 2011 · Open in CIViC

In the breast carcinoma cohort of the phase II TAPUR trial (NCT02693535), patients with BRCA1/2 alterations treated with olaparib (26 evaluable) had 1 CR (BRCA2 loss), 11 PR (BRCA1 n=5, BRCA2 n=4, BRC… (full text at CIViC)

PMID 41100773 · Al Baghdadi et al., 2025 · Open in CIViC

A 55-year-old non-Ashkenazi Spanish female diagnosed with breast cancer (at 51 years old) and ovarian cancer. Sequencing of BRCA1 and BRCA2 revealed a 2-base frameshift insertion in BRCA1 (labeled 302… (full text at CIViC)

PMID 24137399 · Salgado et al., 2013 · Open in CIViC

49-year old woman diagnosed with breast cancer was assessed for BRCA2 mutations. Algorithms including Align-GVGD predicted pathogenicity, however PolyPhen predicted that this variant was benign. The a… (full text at CIViC)

PMID 18951446 · Plon et al., 2008 · Open in CIViC

Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1… (full text at CIViC)

PMID 34081848 · Tutt et al., 2021 · Open in CIViC

The authors show that in the CX-5461 and CX-3543, G-quadruplex stabilizing agents, demonstrate specific toxicity against BRCA deficient breast cancer derived cells and polyclonal patient-derived xenog… (full text at CIViC)

PMID 28211448 · Xu et al., 2017 · Open in CIViC

In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.0… (full text at CIViC)

PMID 25847936 · Isakoff et al., 2015 · Open in CIViC

Randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation HER2–negative metastatic breast cancer. 205 patients we… (full text at CIViC)

PMID 28792849 · 2017 · Open in CIViC

Based on the ability of a Brca2 construct with P655R to rescue the lethality of Brca2-deficient mES cells and its effects on sensitivity to DNA-damaging agents, homologous recombination and genomic in… (full text at CIViC)

PMID 22678057 · Biswas et al., 2012 · Open in CIViC

De novo Alu element insertions were identified within the BRCA2 coding sequences in 3 out of 50 Portuguese families. However, the segregation data and mRNA results in this study were conflicting or in… (full text at CIViC)

PMID 16088935 · Teugels et al., 2005 · Open in CIViC

The E3 ubiquitin ligase, CBLC, was identified as a candidate biomarker for olaparib sensitivity in a siRNA screen and further validated in-vitro in two breast carcinoma cell lines (MCF7 and HS578T). I… (full text at CIViC)

PMID 25883215 · Frankum et al., 2015 · Open in CIViC

A panel of 47 breast cancer cell lines was tested for sensitivty/resistance to CDK4/6 inhibitor Palbociclib (PD0332991), where IC50 below 150nM was sensitive, and above 1000nM resistant. Cyclin D1 ha… (full text at CIViC)

PMID 19874578 · Finn et al., 2009 · Open in CIViC

In this retrospective analysis, CCND1 amplification was analyzed in 442 patients. No interaction with treatment was observed.

PMID 24367492 · Keilty et al., 2013 · Open in CIViC

Cyclin D1 overexpression is associated with the ER-positive subtype of breast cancer.

PMID 15961768 · Arnold et al., 2005 · Open in CIViC

In ER-positive breast cancer patients, Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis.

PMID 15961768 · Arnold et al., 2005 · Open in CIViC

Patients with high expression of total cyclin E and low-molecular weight cyclin E is strongly associated with poor prognosis in breast cancer, and the hazard ratio for these patients in 13.3 times hig… (full text at CIViC)

PMID 12432043 · Keyomarsi et al., 2002 · Open in CIViC

Breast cancer cell lines derived from T-47D (vector control, overexpress cyclin E1, overexpress cyclin E2) were treated with CDK4/6 inhibitor PD0332991 and CDK2 inhibitor SNS-032 as single agents and … (full text at CIViC)

PMID 22564725 · Caldon et al., 2012 · Open in CIViC

This retrospective study analyzed the association between the gene expression and the effectiveness of adding palbociclib to fulvestrant. The PALOMA-3 trial randomly assigned 521 endocrine-pretreated … (full text at CIViC)

PMID 30807234 · Turner et al., 2019 · Open in CIViC

Breast cancer cell lines derived from T-47D (vector control, overexpress cyclin E1, overexpress cyclin E2) were treated with CDK4/6 inhibitor PD0332991 and CDK2 inhibitor SNS-032 as single agents and … (full text at CIViC)

PMID 22564725 · Caldon et al., 2012 · Open in CIViC

Breast cancer cell lines derived from T-47D (vector control, overexpress cyclin E1, overexpress cyclin E2) were treated with CDK4/6 inhibitor PD0332991 and CDK2 inhibitor SNS-032 as single agents and … (full text at CIViC)

PMID 22564725 · Caldon et al., 2012 · Open in CIViC

Sensitivity to durvalumab was tested in patients with triple-negative breast cancer (TNBC) harbouring CD274 gain/amplification. CD274 amplifications were noted in 42% (n=23) of the TNBC samples. Patie… (full text at CIViC)

PMID 33462450 · Bachelot et al., 2021 · Open in CIViC

The results and published literature suggest that in addition to guiding targeted therapy selection, comprehensive genomic profiling shows the potential to identify genomic alterations linked to respo… (full text at CIViC)

PMID 33314633 · Sivapiragasam et al., 2021 · Open in CIViC

In this meta-analysis, 5 studies totalling 2,546 cases were combined to assess the prognostic association of PD-L1 expression in breast cancer. The combined hazard ratio (HR) for PD-L1 overexpression … (full text at CIViC)

PMID 28430626 · Zhang et al., 2017 · Open in CIViC